Find all the latest information
acute myeloid leukemia
, arranged by types, translocations, and mutations.
Listed below are recently updated categories.
Prognostic significance of concomitant gene mutations in intensively treated patients with IDH1/2-mutated AML
At the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation,...
What is the optimal gene panel to be assessed for risk stratification?
The AML Hub was pleased to speak to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE, during the European School...
LDAC plus AC220: Results from the LI-1 trial in older patients with AML
During the 25th European Hematology Association (EHA) Annual Congress 2020, Mike Dennis presented an oral abstract on the...
Molecular landscape and prognostic impact of FLT3-ITD insertion site in AML: An analysis of the RATIFY study
During an oral abstract session at the Virtual Edition of the 25th European Hematology...
Outcomes of two or more HLA loci mismatched unrelated donor allo-HCT: An Acute Leukemia Working Party study
The optimal allogeneic hematopoietic cell transplantation (allo-HCT) results depend on the...
FDA grants BST-236 Fast Track designation for the treatment of older patients with AML
On August 4, 2020, the U.S. Food and Drug Administration (FDA) granted BST-236 (aspacytarabine) Fast Track...
APR-246 plus azacitidine for patients with TP53 mutated MDS and AML
The GFM-APR trial is investigating the safety and efficacy of APR-246 plus AZA as maintenance therapy for patients with TP53 mutant...
Expansion of trial of eprenetapopt in combination with venetoclax and azacitidine in patients with TP53-mutated AML
On July 16, 2020, it was announced that the phase I trial (NCT04214860), evaluating...
Core binding factor
Epigenetic modifier mutations
Signaling pathway mutations
Transcription factor mutations
Tumor suppressor mutations